[1] 赵茂荪. 急性心肌梗死的相关危险因素分析[J],2017,21(17):2218-2219.
[2] 曾庆虹,张晓妍.急性心肌梗死合并2型糖尿病患者的生化指标及冠状动脉病变特点分析[J].江苏医药,2021,47(01):66-68,72.
[3] Wiviott SD, Raz I,Bonaca MP,etal. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.Am Heart J.2018;200:83-89.
[4] Liu X, Zhang S, Chen K, etal. Preventative effects of dapagliflozin on early ventricular dysfunction and remodeling in patients with acute anterior STEMI - The PREDOMINACE trial. Am Heart J Plus.2022 Jul 16;18:100181. doi: 10.1016/j.ahjo.2022.100181. PMID: 38559420; PMCID: PMC10978327.
[5] 中国医师协会急诊医师分会,国家卫健委能力建设与继续教育中心急诊学专家委员会,中国医疗保健国际交流促进会急诊急救分会.急性冠脉综合征急诊快速诊治指南(2019)[J].中华急诊医学杂志,2019,28(4):421-428.
[6] 中国2型糖尿病防治指南(2020年版)(上)[J].中国实用内科学志,2021,41(8):668-695.
[7] Estep JD, Aguilar D. Diabetes and heart failure in the post-myocardial infarction patient. Curr Heart Fail Rep.2006 Dec;3(4):164-9.
[8] Chun BY, Dobson AJ, Heller RF.The impact of diabetes on survival among patients with first myocardial infarction. DiabetesCare.1997May;20(5):704-8.
[9] Furtado RHM, Bonaca MP, Raz I, etal. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation.2019 May28;139(22):2516-2527.
[10] Mao L, Cai D, Chi B, etal. Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis. Eur J Clin Pharmacol.2023 Jul;79(7):915-926.
[11] Zhou L, Geng X, Hu Q,etal. Effects of dapagliflozin on cardiac function and short-term prognosis of patients with both acute myocardial infarction and type 2 diabetes mellitus. Minerva Cardiol Angiol.2024 Jun;72(3):292-298.
[12] Hallow KM, Greasley PJ, Helmlinger G, etal. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. Am J Physiol Renal Physiol.2018 Nov 1;315(5):F1295-F1306.
[13] Shi L, Zhu D, Wang S, etal. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload. Am J Hypertens.2019 Apr 22;32(5):452-459.
[14] 杜阳阳,崔勇波,李海芹.急性心肌梗死PCI术后主要不良心血管事件的发生率及影响因素[J].深圳中西医结合杂志,2023,33(22):118-121.
[15] Donnan PT, Boyle DI, Broomhall J, etal. Prognosis following first acute myocardial infarction in Type 2 diabetes: a comparative population study. Diabet Med.2002 Jun;19(6):448-55.
[16] Gruppetta M, Calleja N, Fava S. Long-term survival after acute myocardial infarction and relation to type 2 diabetes and other risk factors. Clin Cardiol.2010 Jul;33(7):424-9.
[17] Zhu Y, Zhang JL, Yan XJ,etal. Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Cardiovasc Diabetol.2022 Sep 16;21(1):186.
[18] Carvalho LSF Quinaglia T; ADDENDA-BHS2 trial investigators. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovasc Diabetol.2021 Mar 26;20(1):74.
[19] Wang C, Qin Y, Zhang X, etal. Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients. Dis Markers. 2022 Sep 5;2022:5834218.
[20] Joshi SS, Singh T, Newby DE, etal. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart.2021 Jun 11;107(13):1032-1038. |
